Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inflexion Outlines Rosemont Investment And Eyes More Generics Deals

June Deal Was Inflexion’s First In Generics Space

Executive Summary

In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.

You may also be interested in...



Deal Watch: Private Equity-Backed Covis Bids To Buy Troubled AMAG

Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.

Pfizer Faces 15-Year Wait On US Adrenalin Generic

Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.

Trump Most-Favored-Nation Pricing Rule Criticized By The AAM

Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel